Clinical trial
Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or…
NCT00423735 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00423735 |
|---|---|
| Title | Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
| Official title | Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Collaborators | Radiation Therapy Oncology Group NRG Oncology |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm |
| Intervention type | Drug, Other |
| Interventions | Dasatinib, Pharmacological Study |
| Enrollment | 64 |
| Start date | Jan 24, 2007 |
| Primary completion | Mar 9, 2011 |
| Completion | Sep 4, 2018 |
| First posted | Jan 18, 2007 |
| Last update posted | Jul 24, 2019 |
| Countries | Canada, Saudi Arabia, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: